ULMA breaks into the health sector with a diagnostic and analysis solution for diabetic retinopathy screening

Last Friday, November 17, at the Guggenheim Museum Bilbao, ULMA Medical Technologies brought together nearly 150 leading people from the field of healthcare and science.

The event began with a reception for the guests by Josetxo de Frutos, CEO of ULMA Medical Technologies, followed by a scientific session to conclude with the official presentation of ULMA Medical Technologies as a new business initiative of ULMA.

The scientific session began with a keynote presentation by the professor-researcher and consultant of the Andalusian School of Public Health Joan Carles March Cerdá who referred to the challenges and adoption of new technologies in Public Health.

Next, they held a round table in which those responsible for different public Health Services presented several practical cases and their vision of the impact of new technologies on the challenges that Public Health is experiencing today.

During the session, they discussed innovation in the diagnosis and cooperation between the health sector and the industrial field was valued to obtain successful solutions that allow real improvement in health care.

ULMA Medical Technologies presentation

Finally, the main event of the night took place: the official presentation of ULMA Medical Technologies to society as a whole and the healthcare sector in particular. A presentation video and the speech by Josetxo de Frutos, CEO of ULMA Medical Technologies, explained the reason why ULMA is breaking into the Health sector and detailed the software solutions based on Artificial Intelligence that the new company offers.

We have been able to bring together a group of prestigious professionals and top-level actors in the sector, such as our Medical Advisory Committee, and prestigious national and international public and private entities.

Josetxo de Frutos, CEO of ULMA Medical Technologies

CE marking, another important milestone

Along with the presentation at the Guggenheim Museum Bilbao, they fulfilled another important objective in its commitment to innovation in the field. Its UMI DR software has obtained the CE Marking certification for medical devices against Regulation 2017/745 (MDR), which endorses at the highest regulatory and technical level the Artificial Intelligence developed by ULMA for the screening of diabetic retinopathy.

This certification allows them to market its solution throughout the European Union and in other parts of the world. Solutions have already begun to be marketed to prestigious entities in the public and private sectors in the national and international markets.

We work with the conviction that technological innovation can and should be used to improve people’s lives. For this reason, having launched this first project in the field of ophthalmology, we are already working on solutions for glaucoma and macular degeneration and developing solutions in other medical specialities such as dermatology and cardiology.

Josetxo de Frutos, CEO of ULMA medical Technologies

Highlights from the presentation